PapersFlow Research Brief
Adipokines, Inflammation, and Metabolic Diseases
Research Guide
What is Adipokines, Inflammation, and Metabolic Diseases?
Adipokines, inflammation, and metabolic diseases refer to the mechanisms by which adipocyte-derived signaling molecules called adipokines, along with chronic inflammation in adipose tissue, contribute to the development of metabolic disorders including insulin resistance, type 2 diabetes, cardiovascular disease, and metabolic syndrome.
This field examines the relationship between inflammation and obesity, with chronic inflammation in adipose tissue driving obesity-related metabolic disorders such as insulin resistance, cardiovascular disease, and type 2 diabetes. Key studies highlight adipokines, macrophage accumulation, and C-reactive protein as central links between inflammation and metabolic syndrome. The topic encompasses 70,938 works.
Topic Hierarchy
Research Sub-Topics
Adipokines in Obesity-Related Insulin Resistance
This sub-topic investigates adiponectin, leptin, and resistin's roles in adipose-endocrine signaling and glucose homeostasis disruption. Researchers study secretion dysregulation and therapeutic modulation.
Macrophage Polarization in Adipose Tissue Inflammation
This sub-topic explores M1/M2 macrophage shifts, cytokine profiles, and recruitment in obese adipose tissue. Researchers use animal models to link polarization to fibrosis and insulin sensitivity.
C-Reactive Protein and Cardiovascular Risk in Metabolic Syndrome
This sub-topic evaluates CRP as a biomarker linking low-grade inflammation to atherosclerosis in obese cohorts. Researchers conduct prospective studies on CRP's predictive value and anti-inflammatory trials.
Chronic Inflammation in Adipose Tissue Dysfunction
This sub-topic dissects hypoxia, ER stress, and NLRP3 inflammasome activation driving adipocyte hypertrophy. Researchers profile inflammatory mediators in visceral versus subcutaneous fat.
Adipose Tissue Inflammation and Type 2 Diabetes Pathogenesis
This sub-topic links adipocyte-derived TNF-α, IL-6 to β-cell failure and peripheral resistance. Researchers integrate epigenetics and metabolomics in longitudinal diabetic cohorts.
Why It Matters
Adipokines and adipose tissue inflammation directly influence metabolic diseases through pathways that promote insulin resistance and atherosclerosis. Weisberg et al. (2003) in "Obesity is associated with macrophage accumulation in adipose tissue" showed that obesity leads to macrophage accumulation in adipose tissue, releasing proinflammatory molecules that contribute to complications like type 2 diabetes. Hotamışlıgil et al. (1993) in "Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance" demonstrated that tumor necrosis factor-α expression in adipose tissue induces insulin resistance in obesity models. Clinically, Ridker et al. (2017) in "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" reported that canakinumab at 150 mg every 3 months reduced recurrent cardiovascular events by targeting interleukin-1β, independent of lipid lowering, in the CANTOS trial. These findings support anti-inflammatory interventions for managing metabolic diseases linked to obesity.
Reading Guide
Where to Start
"Inflammation and metabolic disorders" by Hotamışlıgil (2006) provides a foundational synthesis of how inflammation in adipose tissue drives metabolic diseases, making it accessible for understanding core mechanisms before diving into specifics like macrophage roles or atherosclerosis.
Key Papers Explained
Hotamışlıgil et al. (1993) in "Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance" first identified TNF-α's direct role in obesity-induced insulin resistance. Weisberg et al. (2003) in "Obesity is associated with macrophage accumulation in adipose tissue" built on this by showing macrophage infiltration as a source of proinflammatory signals. Hotamışlıgil (2006) in "Inflammation and metabolic disorders" integrated these into a broader framework linking inflammation to metabolic syndrome. Ross (1999) and Libby (2002) in "Atherosclerosis — An Inflammatory Disease" and "Inflammation in atherosclerosis" extended the paradigm to cardiovascular outcomes, while Ridker et al. (2017) in "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" provided clinical validation through canakinumab's efficacy.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to explore adipose inflammation's role in insulin resistance and atherosclerosis, as evidenced by highly cited works like Hansson (2005) in "Inflammation, Atherosclerosis, and Coronary Artery Disease." No recent preprints or news in the last 12 months indicate steady progress through established pathways.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Atherosclerosis — An Inflammatory Disease | 1999 | New England Journal of... | 21.6K | ✕ |
| 2 | Inflammation and metabolic disorders | 2006 | Nature | 8.7K | ✕ |
| 3 | Inflammation, Atherosclerosis, and Coronary Artery Disease | 2005 | New England Journal of... | 8.6K | ✕ |
| 4 | Antiinflammatory Therapy with Canakinumab for Atherosclerotic ... | 2017 | New England Journal of... | 8.6K | ✓ |
| 5 | Obesity is associated with macrophage accumulation in adipose ... | 2003 | Journal of Clinical In... | 8.6K | ✓ |
| 6 | The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distrib... | 2017 | Obesity Facts | 8.5K | ✓ |
| 7 | Obesity is associated with macrophage accumulation in adipose ... | 2003 | Journal of Clinical In... | 8.2K | ✓ |
| 8 | Inflammation in atherosclerosis | 2002 | Nature | 8.0K | ✕ |
| 9 | Inflammation and Atherosclerosis | 2002 | Circulation | 7.6K | ✕ |
| 10 | Adipose Expression of Tumor Necrosis Factor-α: Direct Role in ... | 1993 | Science | 7.4K | ✕ |
Frequently Asked Questions
What role do macrophages play in obesity-related inflammation?
Obesity leads to macrophage accumulation in adipose tissue, which alters its metabolic and endocrine function. Weisberg et al. (2003) in "Obesity is associated with macrophage accumulation in adipose tissue" found increased proinflammatory molecules released from these macrophages contribute to obesity-associated complications like insulin resistance.
How does TNF-α contribute to insulin resistance?
Tumor necrosis factor-α (TNF-α) expression increases in adipose tissue of obesity and diabetes models. Hotamışlıgil et al. (1993) in "Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance" showed TNF-α protein elevation locally and systemically impairs insulin action in fat cells.
What is the link between inflammation and atherosclerosis?
Atherosclerosis involves an ongoing inflammatory response triggered by factors like LDL cholesterol. Ross (1999) in "Atherosclerosis — An Inflammatory Disease" established inflammation as central to atherogenesis, while Libby (2002) in "Inflammation in atherosclerosis" detailed its role across disease stages.
How does anti-inflammatory therapy impact cardiovascular events?
Targeting interleukin-1β with canakinumab reduces cardiovascular events. Ridker et al. (2017) in "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" reported a significantly lower rate of recurrent events with 150 mg doses every 3 months compared to placebo.
What defines the metabolic phenotype in obesity?
Obesity's metabolic risks correlate with body fat distribution and adipose tissue dysfunction beyond total adiposity. Goossens (2017) in "The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function" linked impaired adipose function to cardiometabolic disease predisposition.
What connects inflammation to metabolic disorders?
Chronic inflammation links obesity to disorders like type 2 diabetes via adipokines and immune responses. Hotamışlıgil (2006) in "Inflammation and metabolic disorders" outlined how inflammatory processes in adipose tissue drive insulin resistance and metabolic syndrome.
Open Research Questions
- ? How do specific adipokines modulate macrophage polarization in adipose tissue during obesity progression?
- ? What are the precise downstream signaling pathways linking TNF-α from adipocytes to systemic insulin resistance?
- ? Can anti-IL-1β therapies like canakinumab prevent progression from metabolic syndrome to overt type 2 diabetes?
- ? How does adipose tissue macrophage accumulation vary across different obesity phenotypes and fat depots?
- ? What mechanisms underlie the independence of inflammation-driven cardiovascular risk from lipid levels?
Recent Trends
The field maintains a large corpus of 70,938 works on adipokines, inflammation, and metabolic diseases, with sustained high citation rates for foundational papers like Ross at 21,571 citations and Ridker et al. (2017) at 8,619 citations.
1999No growth rate data over 5 years or recent preprints in the last 6 months signal stable research momentum without acceleration.
No news coverage in the last 12 months.
Research Adipokines, Inflammation, and Metabolic Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Adipokines, Inflammation, and Metabolic Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers